FDA approves Cordis Bx Velocity stent:
This article was originally published in Clinica
The US FDA has approved Cordis' PMA supplement to expand the use of its Bx Velocity coronary artery stent to include the elective treatment of de novo and restenotic lesions in native arteries. The product was previously approved for the treatment of lesions considered to be at immediate risk of complete closure. Cordis, a Johnson & Johnson subsidiary, claims the product is available in the broadest range of diameters for coronary arteries in the industry.